Plasmablastic Lymphoma: 28 Patient Single Institution Experience
Patel K, Feng L, Oki Y, et al.
Key Points:
Results of retrospective analyses of clinicopathologic characteristics and survival outcomes of patients with plasmablastic lymphoma (PBL)at single institution reported
Median age 51 years, majority of patients were non-HIV, and most patients had stage IV disease at time of diagnosis
Disease predominantly CD20 negative and treated with variety of dose-intensive chemotherapy regimens
The median PFS and OS were 24.1 and 28.8 months respectively, with early stage disease and younger age at diagnosis recognized as predictive features of favorable outcomes
Implications:
PBL is disease of both HIV+ and HIV– patients with overall survival rate of 40% in patients treated with multi-agent chemotherapy
